BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  New Study: COVID-19 May Cause or Accelerate Neurological Diseases

  Danish researchers published a study suggesting that COVID-19 increases the risk of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.

  June 28, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Spero Searching for Way Forward after FDA Rejects cUTI Drug

  Spero Therapeutics received a Complete Response Letter from the U.S. Food and Drug Administration for its complicated urinary tract infection therapy, tebipenem HBr oral tablets.

  June 28, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Biotech Companies Team Up to Design New Proteins with ML

  Arzeda, Cyrus Biotechnology and Outpace Bio, are teaming up to use machine learning and optimize protein folding and design efforts.

  June 28, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano M.S.
• 

  Harvard Researchers Uncover Insight into T Cells and Autoimmune Disease

  Researchers from Harvard Medical School have published data in Science Daily involving the role of T cells in autoimmune diseases.

  June 28, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Business

  Astellas and Sutro Unite to Overcome Checkpoint Inhibitor Limitations with iADCs

  Astellas Pharma and Sutro Biopharma inked a global collaboration and licensing deal to work to discover and develop novel immunostimulatory antibody-drug conjugates.

  June 28, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Pfizer, Roivant Unveil Priovant with High Potential TYK2/JAK1 Inhibitor

  Pfizer and Roivant unveiled Priovant Therapeutics to develop and market new therapies for a wide range of autoimmune diseases with high mortality and morbidity rates.

  June 28, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Eiger’s HDV Program Sees Cirrhosis in Younger Patients (Updated)

  The findings, presented during a poster session at the EASL 2022 International Liver Congress, revealed that of the 407 D-LIVR participants, nearly 30% developed liver cirrhosis.

  June 28, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Kezar Stock Soars on Positive Lupus Nephritis Data

  Kezar Life Sciences stock rose 92% after it announced positive topline results from its Phase II clinical trial investigating the use of zetomipzomib for the treatment of Lupus Nephritis (LN).

  June 28, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Business

  Dr. Pearl Huang Named CEO of Novartis-Backed Dunad Therapeutics (Updated)

  Pearl Huang, Ph.D, has been appointed the CEO of U.K.-based Dunad Therapeutics, a Novartis-backed biopharmaceutical startup.

  June 28, 2022

   · 

  2 min read

   · 

  Hannah Chudleigh
• 

  Business

  Boehringer Expands BiomX IBD Biomarker Collab, Shutters Crohn’s Trial

  Boehringer and BiomX intend to use the discovery platform to identify biomarkers for a pathogenic bacterium thought to be associated with IBD.

  June 28, 2022

   · 

  3 min read

   · 

  Alex Keown